Elacestrant has demonstrated antitumor activity in vitro and in vivo, including in an ER+HER2- breast cancer model against fulvestrant and cell cycle protein-dependent kinase 4/6 inhibitors as well as in resistance models with mutations in the estrogen receptor 1 gene (ESR1) [116]. Here, ESR1 is linked to breast carcinoma.